BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 5, 2026
Home » Merck & Co. Inc.

Articles Tagged with ''Merck & Co. Inc.''

Biocom space-panel
Drug Design, Drug Delivery & Technologies

Biocom 2023: There’s science going on 250 miles above your head

March 2, 2023
By Brian Orelli
Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth.
Read More
Biocom space-panel

Biocom 2023: There’s science going on 250 miles above your head

March 1, 2023
By Brian Orelli
Performing experiments and potentially manufacturing products in space offers some unique advantages in a near-zero gravity environment. Space changes buoyancy, hydrostatic pressure and convective heat flow. Researchers are studying how those changes affect cells, but also looking to take advantage of the changes to create products in manufacturing processes that wouldn’t be possible on earth.
Read More
Psychiatric disorders illustration
Neurology/Psychiatric

Preclinical characterization and chemical structure of potent and selective PDE10A inhibitor MK-8189 reported

Feb. 13, 2023
Researchers from Merck & Co. Inc. have disclosed the structure and reported preclinical data for MK-8189, a phosphodiesterase 10A (PDE10A) inhibitor.
Read More
Dxcover - CEO - Mark Hegerty

Dxcover reveals $12M in new funding for multi-cancer early detection platform

Feb. 3, 2023
By Annette Boyle
Dxcover Ltd. raised $9.25 million (£7.5 million) in a series A fundraising round and received a grant of $2.7 million (£2.2 million) from the European Innovation Council to support development of the company’s liquid biopsy platform for the detection of multiple early-stage cancers. Existing investors Eos Advisory LLP, Mercia Asset Management plc, Scottish Enterprise, University of Strathclyde, SIS Ventures and Norcliffe Capital led the round, which was also joined by Mark Banforth of Thairm Bio.
Read More
Light bulb shines next to extinguished ones

Spring cleaning starts early as Sanofi and others cut programs

Feb. 3, 2023
By Lee Landenberger
It’s the season for reevaluation as companies weed out programs that don’t offer much promise. At the head of the line is Sanofi SA’s once-potential myasthenia gravis blockbuster tolebrutinib. A partial clinical hold on the phase III study is part of the reasoning for stopping its development. But so is competition, the company said. Other companies eliminating development programs include Roche Holding AG, Gilead Sciences Inc., AB Science SA and Merck & Co. Inc.
Read More

Future of US biosimilar pipeline could rest on Humira competition

Feb. 1, 2023
By Mari Serebrov
A lot of biosimilar sponsors and wannabes will be watching as the Humira biosimilar competition unfolds in the U.S. While the competition started Jan. 31 with the launch of Amgen Inc.’s Amjevita, the true test of the strength of the competition will come in five months when other adalimumab biosimilars, including Boehringer Ingelheim GmbH’s interchangeable, hit the market.
Read More

Supplier exec to pay back insider trading gains

Jan. 30, 2023
By Mari Serebrov
A Jan. 27 settlement the U.S. SEC reached with a former vice president at a biotech company serves as a reminder that insider trading rules applies to suppliers as well as the companies involved in an M&A.
Read More
M&A cityscape

US FTC asked to oppose biopharma M&As that replace R&D

Jan. 30, 2023
By Mari Serebrov
Taking aim at big pharma’s current penchant for acquisition over in-house innovation, Sen. Elizabeth Warren (D-Mass.) is asking the Federal Trade Commission (FTC) to consider the impact a biopharma merger, whether it’s proposed or a done deal, may have on future innovation.
Read More
Streptococcus pneumoniae in lungs

Biopharmas at full strain to find broader PCVs; Vaxcyte, GSK, Merck in play

Jan. 12, 2023
By Randy Osborne
Although strides have been made in the space, biopharma’s hunt for a wider net to cast in vaccines for pneumococcal disease has recruited the likes of Vaxcyte Inc., GSK plc and Merck & Co. Inc., each racing for a candidate with improved valence.
Read More

China grants emergency use authorization for Merck’s COVID-19 drug

Jan. 10, 2023
By Doris Yu
China’s NMPA has approved Merck & Co. Inc.’s COVID-19 treatment molnupiravir for emergency use to combat the increasing number of cases in the country.
Read More
Previous 1 2 … 16 17 18 19 20 21 22 23 24 … 35 36 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • Illustration of a nerve cell with DNA double helix

    Molecular signatures show subtypes in neurodegenerative diseases

    BioWorld Science
    Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
  • Antibodies artwork

    More than two to tango: multispecifics at ESMO TAT

    BioWorld Science
    Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing